Ginkgo Bioworks Holdings (DNA) Change in Receivables (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) reported Change in Receivables of $242000.0 for Q1 2026, down 63.72% on a YoY basis from $667000.0 in Q1 2025, and down 86.69% quarter-over-quarter from $1.8 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Change in Receivables (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Change in Receivables for 7 years, with the latest figure at $242000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables fell 63.72% year-over-year to $242000.0; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (up 176.05% YoY), and the FY2025 full-year result was $1.5 million, down 68.83% from the prior year.
- Change in Receivables for Q1 2026 stood at $242000.0, down from $1.8 million in the prior quarter.
- The five-year high for Change in Receivables was $34.9 million in Q1 2022, with the low at -$59.1 million in Q3 2022.
- Historically, Change in Receivables has averaged -$5.8 million across 5 years, with a median of -$255000.0 in 2025.
- Annual changes were most pronounced in 2023 — Change in Receivables plunged 533.87% — and 2024, when it jumped 1187.07%.
- Ginkgo Bioworks Holdings' Change in Receivables stood at -$34.5 million in 2022, then grew by 16.24% to -$28.9 million in 2023, then soared by 95.24% to -$1.4 million in 2024, then jumped by 232.12% to $1.8 million in 2025, then plunged by 86.69% to $242000.0 in 2026.
- The last three Change in Receivables figures came in at $242000.0 (Q1 2026), $1.8 million (Q4 2025), and -$757000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn | 242,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 242,000.00 |
| Mar 31, 2026 | 242,000.00 |
| Dec 31, 2025 | 1.82 Mn |
| Dec 31, 2025 | 1.82 Mn |
| Sep 30, 2025 | -757,000.00 |
| Sep 30, 2025 | -757,000.00 |
| Jun 30, 2025 | -255,000.00 |
| Jun 30, 2025 | -255,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Dec 31, 2024 | -1.38 Mn |
| Dec 31, 2024 | -1.38 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | -5.67 Mn |
| Jun 30, 2024 | -5.67 Mn |
| Mar 31, 2024 | 6.77 Mn |
| Mar 31, 2024 | 6.77 Mn |
| Dec 31, 2023 | -28.90 Mn |
| Dec 31, 2023 | -28.90 Mn |